interest for scientists and clinicians because such sites are among the most critical for proper protein function. Indeed, a majority of amino acid mutations that have been investigated experimentally are located at ultraconserved sites 1 , which show no amino acid residue difference among diverse species spanning over 500 million years of evolution ( Supplementary Fig. 1 ). Functionally damaging mutants at these sites are likely to have significant consequences for health and disease.
For these ultraconserved sites, we estimated the false positive rate (FPR) of two state-of-the-art computational tools, Condel 2 and PolyPhen-2 (ref. 3) , by using the standard collection of neutral variants (HumVar 3 ) that was used to train and test these two tools ( Table 1) .Our analysis revealed a high FPR for Condel (89%) and PolyPhen-2 (75%). For 73% of the neutral nSNVs in HumVar, both produced a function-damaging prediction. Additionally, the overall accuracy of these tools at ultraconserved positions was low (55% and 60%, respectively). Therefore, predictions produced by current computational tools may mislead downstream experimental and clinical investigations aimed at studying functionally important sites.
To remedy this problem, we have developed a method that adaptively fits the best prediction model for nSNV sites evolving at distinctly different rates as revealed by multispecies comparison (ultra-, well-and less-conserved, Supplementary Fig. 1 ). Our Evolutionary Diagnosis (EvoD) method considers fundamental evolutionary properties of affected sites and amino acid changes, including measures of the biochemical severity and evolutionary probability of the amino acid change, as well as multilevel taxonomic evolutionary rates and time spans of the position affected. Within a sparse learning framework, the ability of these properties to explain the observed (training) data was evaluated in EvoD to establish an
Evolutionary diagnosis method for variants in personal exomes
To the Editor: Each human exome contains thousands of nonsynonymous single-nucleotide variants (nSNVs) that have unknown biological effects. The potential impact of nSNVs on biological function is now routinely assessed using computational methods for application in biomedical research and clinical genome profiling reports. Of the variants receiving a non-neutral (function-damaging) prediction, those at evolutionarily conserved sites are frequently of heightened (c) Neutrality heat maps based on EvoD predictions for homozygous (Hom.) and heterozygous (Het.) nSNVs from eight HapMap exomes that occur at ultra-, well-and lessconserved sites. Heat maps were constructed by sorting nSNVs by impact score and assigning colors from dark blue (most neutral) to red (most nonneutral) on a linear scale according to the estimated P value. Figs. 2-5) . A web server for evaluating novel variants with EvoD is available at http://barn.asu.edu/EvoD/. At ultraconserved sites, EvoD led to large reductions in the FPR: 55% for Condel and 41% for PolyPhen-2. We retrieved the population allele frequency of the neutral HumVar nSNVs at ultraconserved sites from a 5,400-exome data set 4 and found that EvoD improved diagnoses across the spectrum of rare (<0.1%) to common (>5%) alleles (Fig. 1a) . The balanced accuracy of EvoD was also significantly higher than that of Condel and PolyPhen-2 at ultraconserved sites ( Table 1 ; P < 10 -10 ). Furthermore, EvoD's performance was consistent across ultra-, well-and less-conserved sites, whereas Condel and PolyPhen-2 showed uneven performance across these classes ( Table 1) .
For each nSNV, the EvoD statistical model also produced an impact score that reflected the degree of neutrality: most neutral = 0 and most non-neutral = 100. In an analysis of 244,272 nSNVs from the 1000 Genomes Project, we found that the population frequency of nSNVs decayed with increasing impact score (Fig. 1b) . We therefore used the empirical distribution of EvoD scores to determine the statistical significance of a neutral or non-neutral diagnosis (P value) adaptively for variants at ultra-, well-and less-conserved sites (Supplementary Fig. 2 ).
Using EvoD, we analyzed nSNVs in an example set of eight personal HapMap exomes 5 containing a total of 13,372 nSNVs at ultraconserved sites. Of these, 4% were predicted to be non-neutral (P < 0.05). An overwhelming majority (94%) of these non-neutral nSNVs were found in heterozygous genotypes that would neutralize the negative effects of recessive alleles. Similar results were observed for 35,367 nSNVs at well-and less-conserved sites, which were also reflected in the neutrality heat maps showing the EvoD impact scores of nSNVs in heterozygous genotypes (Fig. 1c) . In contrast, the fraction of homozygous nSNVs with high EvoD impact scores was much smaller at ultraconserved sites (Fig. 1c) . EvoD predicted no more than one homozygous nSNV per exome to be non-neutral (P < 0.05) in ultraconserved sites, which is consistent with the fact that individuals contributing to HapMap sequencing do not suffer from any known Mendelian disease.
Our results show that an evolution-aware approach to training and testing computational tools leads to better functional predictions for nSNVs, particularly at the most functionally important positions. 
neonatal desensitization does not universally prevent xenograft rejection
To the Editor: Human cells transplanted into immunocompetent animals are generally rejected within 2-4 weeks 1 . Severe immune suppression is capable of protecting the grafted cells; however, such treatment is associated with unacceptable side effects 2 . An important advancement in the field was the introduction of immunodeficient animal models that accept xenografts, but these are poor models for human diseases 3 . A paper published in Nature Methods proposed neonatal desensitization without an overall suppression of the immune system 4 as an alternative. Encouraged by this study, we attempted to use neonatal desensitization to protect grafts of two types of human cells in mice and rats (Fig. 1) . The experiments were conducted in two independent laboratories.
The first cell type we tested was immortalized, luciferaseexpressing human glial-restricted precursor (hGRP) cells derived from fetal brain (Q Therapeutics). We induced neonatal desensitization by intraperitoneal injection of 1 × 10 5 hGRP cells into BALB/c mice. The experiment was repeated three times using a total of 37 mice (Supplementary Methods). hGRPs initially npg
